Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|N0949||NCCTG||Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|ACNS0224||COG||A Phase I/II Study of Topotecan with G-CSF and Radiation Therapy In Children with Malignant Intrinsic Pontine Brainstem Gliomas of Childhood||Pediatric CIRB||Completed|
|S0012||SWOG||A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-38||NSABP||A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-90202||CALGB||A Randomized Double-Blind; Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0250||GOG||A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297||Adult CIRB - Late Phase Emphasis||Completed|
|S1300||SWOG||A Randomized; Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systematically After Previous Clinical Benefit From Crizotinib Monotherapy<br>||Adult CIRB - Early Phase Emphasis||Completed|
|ACCL04C2||COG||Randomized Study of Electroacupuncture Treatment for Delayed Chemotherapy-induced Nausea and Vomiting in Patients with Pediatric Solid Tumors 02-AT-0172||Pediatric CIRB||Completed|
|CALGB-70301||CALGB||Quality of Life; Employment; and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101||Adult CIRB - Late Phase Emphasis||Completed|
|ACOSOG-Z9031||ACSOG||A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS)||Adult CIRB - Late Phase Emphasis||Completed|